StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Oncology — Established RoW product sales by Quarter

Oncology — Established RoW product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Oncology — Established RoW product sales: $620M in Q2 2026, up 4.9% from a year earlier. That is the highest of the 23 quarters on record here.

Latest, Q2 2026
620
Period ended Jun 30, 2026
Change on a year earlier
+4.9%
591 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| Oncology | 6,713 | | 15 | | 13 | | 3,163 | | 14 | | 1,522 | | 16 | | 12 | | 1,408 | | 19 | | 14 | | 620 | | 5 | | 10”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Therapy Area Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOncology — Established RoW product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026620+4.9%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026549+13.4%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025619+10.1%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025586+9.3%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025591+5.3%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025484-7.1%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024562-2.9%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024536-8.1%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024561-8.6%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024521+6.3%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 2023579+27.5%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 2023583+28.4%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023614+20.9%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 2023490+4.5%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 2022454-12.9%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 2022454-8.7%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up oncology — Established RoW product sales

Cite this data

StockData. (2026). AstraZeneca Oncology — Established RoW product sales ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ta-oncology-erow

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.